Health Care Services

Nano-X Imaging

Tencent

Financial Analysis

00700

AIMID

GOOG

GOOGL

NNOX

000656

TCTZF

TCEHY

80700

GGLS

GGLL

NANO

HTCD

SBCWW

After the Hong Kong stock market closed on November 13, Beijing time, $TENCENT(00700.HK) released its third-quarter 2025 results. Overall, while there were not many surprises compared to expectations, stability remains the key theme, with no significant weaknesses in the three major business lines. Since the beginning of this year, Tencent has entered a new investment cycle, yet traces of the management's refined operations and effective capital allocation can still be observed. Specifically: 1. Gaming remains the standout: Tencent Games maintained high growth of 23% in the third quarter, driven by the product cycle. Overseas, under the leadership of Supercell's 'Clash Royale,' it continued to surge (with favorable exchange rate contributions)...

TENCENT

Meta Platforms

AIM IMMUNOTECH INC

AIM ImmunoTech

Alphabet - C

Alphabet

JINKE PROPERTY

SBC Medical

Tencent Holdings Limited

TENCENT-R

Direxion Daily Googl Bear 1x Shares

Direxion Daily GOOGL Bull 2X Shares

Pro Ultra 7-10Yrs

Nanoco Group PLC

Tencent HK SDR 10to1

SBC MEDICAL GROUP HOLDINGS INCRPRTD C/WTS 17/09/2029 (TO PUR COM)

Tencent: Not playing heartbeats with Meta, just seeking stable happiness

Nano-X Imaging released FY2025 earnings on April 20 Pre-Market (EST), actual revenue USD 13.02 M (forecast USD 13.29 M), actual EPS USD -1.1578 (forecast USD -0.8725)

Nano-X Imaging released FY2025 Q4 earnings on April 20 Pre-Market (EST), actual revenue USD 3.719 M (forecast USD 3.994 M), actual EPS USD -0.4976 (forecast USD -0.2225)

Nanox Signs Business Agreement with Howard Technology Solutions to Deploy Nanox.ARC Systems

Nano-X Imaging to Release FY2025 Q4 Earnings on April 20, 2026 Pre-Market EST, Forecast Revenue USD 3.994 M, EPS USD -0.1925

Nano-X Imaging Ltd. to Showcase New Clinical Data on Bone Solution at ECR

Nanox.AI's Spinal Assessment Technology Recommended for Early Value Assessment by NHS

Nano-X Imaging released FY2025 Q3 earnings on November 20 Pre-Market EST, actual revenue USD 3.447 M (forecast USD 3.505 M), actual EPS USD -0.2127 (forecast USD -0.2133)

Nano-X Imaging released FY2025 9 Months earnings on November 20 Pre-Market EST, actual revenue USD 9.302 M, actual EPS USD -0.6501

Nano-X Imaging Ltd Acquires VasoHealthcare IT Inc to Enhance AI-Driven Medical Imaging Technology

Nano-X Imaging to release FY2025 Q3 earnings on November 20 Pre-Market EST, forecast revenue USD 3.505 M, EPS USD -0.2133

Nano-X Imaging released FY2025 Semi-Annual Earnings on August 12 Pre-Market EST, with actual revenue of USD 5.855 M and EPS of USD -0.4377

Nano-X Imaging released FY2025 Q2 earnings on August 12 Pre-Market EST, actual revenue USD 3.04 M (forecast USD 3.2 M), actual EPS USD -0.2303 (forecast USD -0.19)

Nano-X Imaging to Release FY2025 Q2 Earnings on August 12 Pre-Market EST, Forecast Revenue USD 3.2 M, EPS USD -0.19

Nano-X and Kaiser University Partner to Promote 3D Medical Imaging Education

D. Boral Capital Maintains Buy Rating on Nano X Imaging

Nanox AI Obtains EU Medical Device CE Certification

Nano-X Imaging Ltd reports Q1 EPS loss of 21 cents, revenue missed expectations

Nano-X Imaging released FY2025 Q1 earnings on May 22 Pre-Market EST, actual revenue USD 2.815 M (forecast USD 3.977 M), actual EPS USD -0.207 (forecast USD -0.1925)

Nano X Imaging to Report Earnings on May 22, 2025

Nano-X Imaging Ltd to Post 19 Cent Loss Per Share, Revenue Up 56%

OPTIMI HEALTH CORP

Silexion Therapeutics

HCW Biologics

FLAG SHIP ACQUISITION CORPORATION COM USD0.001 (SUB/RIGHT 31/03/2026)

Micware

GCL Global

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

Arcadia Biosciences

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

NANO-X IMAGING LTD (NNOX) will announce its Q1'26 earnings on May 27 at 8:00 AM ET. The revenue estimate is 5.51 million USD, with an anticipated EPS of (0.16) USD. Previous quarters showed reported revenues of 2.81M, 3.04M, 3.45M, and 3.72M, with varying revenue surprises. EPS reported for the last four quarters were (0.21), (0.23), (0.21), and (0.50).

TradingView

iShares US Medical Devices

SPDR S&P Health Equip

NNOX Q1'26 Earnings: revenue estimate is 5.51M USD

Kirby McInerney LLP is investigating potential claims against Nano-X Imaging Ltd. (NASDAQ:NNOX) regarding possible violations of federal securities laws. This follows Nano-X's announcement of a $33.4 million net loss for Q4 2025, largely due to asset impairment charges, and the resignation of CFO Ran Daniel. Following this news, Nano-X's stock price fell by approximately 25%. No lawsuit has been filed yet, and the investigation is ongoing. Investors with information or interest are encouraged to contact the law firm for further details.

MorningStar

NNOX INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Nano-X Imaging Ltd.

Nano-X Imaging has entered a strategic agreement with Howard Technology Solutions to deploy 300 Nanox.ARC systems over three years, enhancing its market presence. The company reported a narrower Q4 loss of 17 cents per share but missed revenue estimates with $3.72 million. A restructuring plan aims to improve margins and efficiency, including winding down operations in South Korea and focusing on R&D. The total restructuring cost is estimated at $18 million, with fiscal 2026 sales guidance reaffirmed at $35 million. NNOX shares fell 7.36% to $2.01, marking a new 52-week low.

benzinga_article

Growth Deal Meets Restructuring As Nano-X Eyes Margin Improvement

KNSA

The health care sector's oversold stocks present buying opportunities, with Kiniksa Pharmaceuticals (KNSA), Nano-X Imaging (NNOX), and Atrium Therapeutics (RNA) identified as top picks. KNSA has an RSI of 28, with a recent price drop to $42.46. NNOX, with an RSI of 28.2, fell to $2.16 after disappointing sales. RNA, at an RSI of 28.4, closed at $14.30. Analysts suggest these stocks may lead to significant gains this month due to their undervalued status.

Kiniksa Pharmaceuticals

Atrium Therapeutics

Top 3 Health Care Stocks That Could Lead To Your Biggest Gains This Month

Nano-X Imaging (NNOX) reported Q3 FY 2025 revenue of US$3.4 million, with a basic EPS loss of US$0.21, while trailing twelve-month revenue stands at US$12.3 million and a net loss of US$55.7 million. Despite a slight revenue increase, losses remain significant, raising concerns about the company's path to profitability. Analysts highlight high operating costs and a small revenue base as challenges. Forecasts suggest ambitious growth, but the current P/S ratio of 12.2x indicates high expectations that may not align with actual performance.

Simplywall

Nano X Imaging (NNOX) Quarterly Losses Far Exceed US$3.4m Revenue Reinforcing Bearish Narratives

Nano-X Imaging Ltd. reported its Q4 earnings, highlighting a cautious balance between growth and financial strain. The company secured a major deal for deploying 300 Nanox.ARC systems and reported a 23% revenue increase to $3.7 million, driven by teleradiology. However, it faced a GAAP net loss of $33.4 million, largely due to asset impairment. The company aims for $35 million in revenue for 2026, contingent on activating new distribution channels. Despite expanding its technology and regulatory achievements, challenges in hardware economics and rising operational costs remain significant concerns.

Tip Ranks

Nano-X Imaging Balances Growth Hopes With Deepening Losses

Nano-X Imaging shares are trading lower after the company reported worse-than-expected Q4 sales results.

Nano-X Imaging(NNOX.US)